Respiratory Diseases Respiratory Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
CHMP_opinion_nintedanib_ILD_PF CHMP_opinion_nintedanib_ILD_PF Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
EC_approval_nintedanib_ILD_PF EC_approval_nintedanib_ILD_PF European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
New data for nintedanib in children with fibrosing ILD New data for nintedanib in children with fibrosing ILD InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Investigational treatment slowed lung function decline in IPF Investigational treatment slowed lung function decline in IPF Investigational treatment slowed lung function decline in IPF
FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Boehringer-Ingelheim's-half-year-figures-2021 Boehringer-Ingelheim's-half-year-figures-2021 Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Better Access to Healthcare for Indigenous Peoples Better Access to Healthcare for Indigenous Peoples Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study